Table 2.

Response rates of patients with and without brain metastases to first-line single-agent pembrolizumab

	With brain metastases		Without brain metastases
	N = 176	% (95% CI)a	N = 669	% (95% CI)a
Best response
Objective response rate (ORR)b	N = 80	47 (39–55)	N = 291	45 (41–49)
Stable disease	N = 36	20 (14–26)	N = 153	23 (20–26)
Progressive disease	N = 55	31 (24–38)	N = 206	31 (27–34)
Not evaluable	N = 5	–	N = 19	–

NA not applicable

^aExact method for binomial confidence interval

^bComplete response plus partial response rates